Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

The projected decline in AJANTPHARM's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 2.854000
forwardPE 26.704838
debtToEquity 1.343000
earningsGrowth 0.119000
revenueGrowth 0.110000
grossMargins 0.754120
operatingMargins 0.219210
trailingEps 73.620000
forwardEps 99.280000

Ajanta Pharma Limited's current ratio is 2.854, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as Ajanta Pharma Limited should not face any issues meeting its short-term liabilities with available resources.
AJANTPHARM's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
AJANTPHARM's positive earnings and revenue growth suggest the company is on a path to business expansion. This upward trend signals strong financial health, indicating that AJANTPHARM is well-positioned for sustained growth in both profits and revenue.
Positive gross and operating margins for Ajanta Pharma Limited demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
AJANTPHARM's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in AJANTPHARM's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

AJANTPHARM's price projections have gradually decreased, indicating a more conservative outlook from analysts. The repeated downward revisions suggest waning confidence in the company's ability to achieve its previous targets.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


14 sales transactions of AJANTPHARM were conducted, with market price at 2891.067853655134.During the period under consideration, no sell transactions took place.The higher number of buys versus sells near AJANTPHARM's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


AJANTPHARM has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view AJANTPHARM as a reliable choice for their money, offering a promising avenue for future growth and financial gains.